Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.
The authors investigated the impact of IVIg as first line treatment of diabetic patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) concomitant with distal symmetric axonal polyneuropathy. Nine patients with these clinical and electrophysiological features were treated with IVIg (0.4 g/Kg/day for 5 days). Clinical and electrophysiological evaluations were performed before and after treatment. Following IVIg treatment there was no significant improvement in clinical deficit. However, there was a significant and persistent decrease in the Rankin scale score and an improvement in the demyelinating feature on nerve conduction studies. Our findings suggest that IVIg had small but detectable beneficial effects on diabetic patients with CIDP and a high degree of axonal damage.
U. O. A. D. U. Neurologia I, Dipartimento di Neuroscienze, Università di Torino, Via Cherasco 15, 10126 Turin, Italy. dariococito@yahoo.it
Dario
D
Cocito
Palma
P
Ciaramitaro
Gianluca
G
Isoardo
Pierangelo
P
Barbero
Giuseppe
G
Migliaretti
Antonio
A
Pipieri
Giuliana
G
Proto
Roberto
R
Quadri
Bruno
B
Bergamasco
Luca
L
Durelli
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D009431:Neural Conduction / Q000187:drug effects / Q000276:immunology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D020127:Recovery of Function / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous